Thought disorders among non-demented outpatients with Parkinson's disease: prevalence and associated factors.
The objectives of the study are to evaluate the prevalence and the associated factors of thought disorders in a large cross-sectional population of non-demented out patients with Parkinson's disease (PD). Four-hundred and nineteen consecutive non-demented PD patients were studied through the DoPaMiP cross-sectional study. Demographic and clinical variables were recorded, including motor and cognitive status, dependency, depressive and anxious symptoms, dysautonomia and sleep disorders. The presence of thought disorders over the past 15 days was assessed by the Unified Parkinson's Disease Rating Scale part I. Patients with and without thought disorders were compared using parametric tests. Logistic regression was applied to significant data. Thought disorders were present in 105 patients (25%) including vivid dreams in 83 (19.8%), benign hallucinations in 17 (4.1%), and hallucinations without insight in 5 (1.2%). No patient had delusion. Patients with thought disorders were more dependent than the others. Thought disorders were associated with longer PD duration, greater UPDRS scores and the presence of motor complications. Conversely, UPDRS tremor sub-score was lower in patients without thought disorders. Thought disorders were also associated with dysautonomia, lower MMSE score, depression and sleep disorders. Logistic regression identified PD duration, lower MMSE score, depressive and dysautonomic signs as independent risk factors. In conclusion, mild thought disorders were present in 25% of non-demented outpatients with PD, but hallucinations were present in 5% only. Thought disorders were associated with PD duration, depressive and dysautonomic symptoms and lower MMSE score.
Debs
Rachel
R
Department of Neurosciences, University Hospital, Toulouse, France.
Cochen De Cock
Valérie
V
Nègre-Pagès
Laurence
L
Aristin
Marina
M
Senard
Anna
A
Rascol
Olivier
O
D000368:Aged; D000369:Aged, 80 and over; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology; D015897:Comorbidity; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology; D008875:Middle Aged; D010300:Parkinson Disease / Q000453:epidemiology* / Q000523:psychology; D015995:Prevalence; D012307:Risk Factors
Neurology. 1997 Aug;49(2):393-9
9270567
Brain. 2007 Jul;130(Pt 7):1787-98
17535834
Mov Disord. 1999 Jan;14(1):117-21
9918353
J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):727-33
11385004
Mov Disord. 2008 Mar 15;23(4):484-500
18175343
Mov Disord. 2006 Dec;21(12):2110-5
17013922
Am J Ophthalmol. 2000 Aug;130(2):261-2
11004314
Brain. 2007 Aug;130(Pt 8):2123-8
17586867
Neurology. 2009 Nov 3;73(18):1469-77
19884574
Arch Neurol. 1996 Dec;53(12):1265-8
8970453
Neurology. 2000 Jul 25;55(2):281-8
10908906
Neurology. 1995 Apr;45(4):669-71
7723953
Mov Disord. 2003 Jul;18(7):812-7
12815661
Psychiatry Res. 1989 May;28(2):193-213
2748771
Mov Disord. 2007 Jul 30;22(10):1510-1514
17516497
Neurology. 2005 Jan 11;64(1):81-6
15642908
Pain Suppl. 1986;3:S1-226
3461421
Arch Neurol. 1999 May;56(5):595-601
10328255
Sleep Med. 2008 Jul;9(5):473-4
18024175
Brain. 2009 Nov;132(Pt 11):2947-57
19759203
JAMA. 1969 May 19;208(7):1168-70
5818715
Neurology. 1993 Nov;43(11):2227-9
8232934
J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):734-8
11385005
Mov Disord. 2005 Nov;20(11):1439-48
16028215
Clin Neuropharmacol. 2002 Nov-Dec;25(6):318-24
12469006
Age Ageing. 1997 Sep;26(5):353-7
9351479
Neurology. 1997 Sep;49(3):724-8
9305331
Ann Neurol. 1993 Nov;34(5):710-4
8239565
Mov Disord. 2008 Jul 30;23(10):1361-9
18546344